News | News By Subject | News by Disease News By Date | Search News

Bleeding News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Why Rigel (RIGL)'s Layoffs May Not be a Bad Thing     9/19/2016
Bay Area's Rigel (RIGL) Slashes 38% of Workforce; Shifts From R&D to Commercial Operation     9/16/2016
Rigel (RIGL)'s Bleeding Disorder Drug Passes First of Two Key Late-Stage Trials     8/30/2016
Defective Device Forces Regulators to Take a Hard Look at Bayer (BAY)'s Xarelto Trial     12/9/2015
FDA Gives Nod to Baxalta (BXLT)'s Rare Bleeding Disorder Drug Vonvendi     12/9/2015
Baxter International (BAX)'s Bleeding Disorder Drug Delivers 100% Success Rate in Late-Stage Study     4/21/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Boehringer Ingelheim Corporation Says New Bleeding Cases Found In Pradaxa Study     5/15/2014
Alnylam Pharmaceuticals (ALNY) Reports Initial Positive Top-Line Data From Phase 1 Clinical Trial With ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) In Development For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)     5/13/2014
FDA: Boehringer Ingelheim Corporation's Pradaxa Benefit Outweighs Bleeding Risk     12/8/2011
Novo Nordisk A/S (NVO) Bleeding Drug May Harm Hospital Trauma Patients, Study Says     4/19/2011
FDA Approves Exelixis, Inc. (EXEL) Product to Prevent Bleeding in People With Rare Genetic Defect     2/18/2011
Merck & Co., Inc. (MRK) Says Clot Preventer has Bleeding Risk     1/20/2011

News from Around the Web
A New Hydrogel Made From Snake Venom Stops Bleeding In Seconds, Rice University Reveals     10/27/2015
Denying Vitamin K Puts Infants At Risk For Rare Bleeding Disorders, Centers for Disease Control and Prevention (CDC) Reports     11/15/2013
American Society of Hematology: No Excess Bleeding With Apixaban in Hip, Knee Trial, University of Oklahoma Study     12/6/2010
Blood Thinning Drug Warfarin Linked To Increased Bleeding In Brain, University of Cincinnati Study     9/30/2008
Antidepressants Tied To Gastrointestinal Bleeding, Spanish Agency for Medicines and Healthcare Products Study     7/8/2008
Coagulation Factor VIIa Provides Less Hemorrhaging After Stroke, But Not Fewer Deaths, University of Heidelberg Study     6/11/2008
Genetic Test Predicts Response to Warfarin     3/6/2008
Anti-Clotting Drug Trial Shortened by Bleeding Problems     1/25/2008
Asians Prone to Bleeding with Anti-Clotting Drugs     9/13/2007
Clinical Trial On Dysfunctional Uterine Bleeding (DUB) Now Conducted By Thomas L. Lyons, MD, GYN Surgeon     7/31/2007
African Plant Halts Bleeding, Speeds Healing     7/27/2007
Gel Made from Patient's Blood Speeds Healing, University of Cincinnati Medical Center Study Finds     5/22/2007
Patients with "Bleeding" Strokes Less Likely to Get Prevention Treatment     5/11/2007
Antibiotic Linked to Serious Bleeding Condition     3/1/2007
Gel Stops Bleeding In Seconds     10/10/2006

Press Releases
Shire (SHPG) Release: Topline Results Of Phase 3 Investigational Study Of VONVENDI [Von Willebrand Factor (Recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding And Blood Loss During Surgical Procedures     12/2/2016
Portola (PTLA) Announces Andexxa™ (Andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society of Hematology Annual Meeting And Exposition     11/28/2016
Portola (PTLA) Announces Three Phase III APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban     11/15/2016
Baxter International (BAX) Initiates Clinical Trial For Citrate Anticoagulant For Use During Continuous Renal Replacement Therapy     11/2/2016
Portola (PTLA) Submits New Drug Application To FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients     10/25/2016
Viveve Snags FDA Nod for the Viveve System in the U.S.     10/7/2016
Johnson & Johnson (JNJ) Allegedly Failed to Disclose Faulty Device Concerns in Xarelto Trial     9/30/2016
Portola (PTLA) Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting     9/13/2016
Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting The Potential Clinical And Health Economic Impact Of EG-1962 In Aneurysmal Subarachnoid Hemorrhage     9/7/2016
Portola (PTLA) Announces Interim Results From Ongoing Phase IIIb/IV ANNEXXA-4 Study Of Factor Xa Inhibitor Antidote Andexxa (Andexanet Alfa) In Patients With Acute Major Bleeding     8/30/2016
Amerigen Pharmaceuticals Announces Final Approval From FDA For Generic Version Of Lysteda     8/2/2016
Edge Therapeutics Announces First Patient Treated In Phase III NEWTON 2 Study Of EG-1962 In Adult Patients With Aneurysmal Subarachnoid Hemorrhage     7/29/2016
Children's Hospital of Philadelphia Release: Bio-Engineered Molecule Shows Promise For Quick Control Of Bleeding     7/26/2016
Verseon (VSN.L) Presents Further Trial Data On The Low Bleeding Risk Of Its Family Of Preclinical Anti-Coagulant Drugs At BioEurope Conference     4/11/2016
Bio Products Laboratory Receives European Approval For Coagadex (Human Coagulation Factor X)     3/30/2016

//-->